SUBSCRIBE
SUBSCRIBE
News   Policy

FDA Says GlaxoSmithKline Drug Promacta Fails to Control Bleeding

May 29, 2008 | 
1 min read

WASHINGTON - An experimental drug from GlaxoSmithKline does not significantly lower bleeding in patients with a rare blood disorder, according to the Food and Drug Administration.

Regulatory
GlaxoSmithKline Food and Drug Administration (FDA)
MORE ON THIS TOPIC
Pictured: J&J's building in Switzerland
Legal
J&J Pulls $7B Commitment as Court Swats Final Talc Settlement Plan
April 2, 2025
 · 
2 min read
 · 
Tristan Manalac
A woman's hand holding a scale.
Government
Democrats Push Back on Trump Health Cuts With Lawsuits and Longest Ever Senate Speech
April 2, 2025
 · 
2 min read
 · 
Tristan Manalac
Podcast
FDA on Fire, Novo’s Mixed Bag of Semaglutide Cardio Data, Kisunla’s EU Miss, More
April 2, 2025
 · 
1 min read
 · 
Heather McKenzie
Creative collage hand cutting dynamic arrow progress statistic rise up reach target positive result top improvement drawing background.
FDA
Biotech’s ‘Worst Fear’ Comes True as FDA’s Marks Departs, Sending Shares Tumbling
April 1, 2025
 · 
3 min read
 · 
Annalee Armstrong